Market News How it works Learn FAQ
| RCT 0.1382 81.60% | NU 11.97 -21.04% | TGL 0.2617 18.15% | EWZ 32.715 -23.19% | SRTM 0.3394 -21.12% | BBD 2.835 -30.34% | SHFS 0.0989 -25.30% | GCDT 0.1322 -24.93% | ITUB 7.368 -23.81% | NWGL 0.0817 -0.37% | CLRO 4.67 43.69% | XP 14.8623 -51.13% | AZTR 1.265 76.92% | RBNE 0.1664 -12.42% | PBR 21.535 -17.68% | SGRY 23.055 46.38% | SOXL 85.96 2.87% | TSLL 10.8899 11.58% | SPCX 147.535 0.03% | VALE 12.0045 -3.19% | SPRC 1.4499 33.02% | NVD 4.04 -3.58% | CRWV 54.96 1.34% | JBLU 2.2085 -15.87% | SOXS 51.01 -2.76% | INTC 87.29 0.38% | GPUS 0.1679 -0.59% | NVDA 215 1.92% | TSLA 394.1 5.88% | IREN 24.64 -1.06% | ABEV 2.7991 -15.18% | TQQQ 67.83 2.32% | RENT 2.9899 30.00% | NOK 8.46 3.93% | INTR 4.415 -38.60% | PBR-A 18.92 -19.59% | XTND 2.8083 58.66% | SQQQ 38.76 -2.32% | BITO 10.6402 -1.75% | LUCD 0.5437 32.29% | SPDN 8.495 -0.53% | VBIO 0.8098 -13.85% | SBS 4.765 -25.55% | XXII 0.0999 -49.47% | SID 0.9233 -21.75% | STNE 7.96 -30.66% | KORU 10.6 0.19% | WFF 0.0765 -4.38% | RWM 14.4501 -0.69% | TSLG 5.45 11.91%
MDMadrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ Global Select · Currency in USD
$440.16 ▲ +5.92 (+1.36%)
As of Oct 26, 11:25 AM ET. Market open.

Summary

Previous Close
$434.24
Open
$435.66
Day's Range
$432.12 – $442.41
52 Week Range
$393.61 – $615.00
Volume
54,738
Avg. Volume
326,241
Market Cap
$10.17B
Beta (5Y Monthly)
-1.05
PE Ratio (TTM)
--
EPS (TTM)
-$11.15
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$686.44

Profile: Madrigal Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
915
CEO
William J. Sibold

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.86 · Revenue est. $404.17M
DateEst.Actual
Jul 30, 2026-$2.68-$1.99Beat
May 6, 2026-$3.61-$3.25Beat
Feb 19, 2026$0.04-$2.57Miss
Nov 4, 2025-$2.04-$5.08Miss
Aug 5, 2025-$3.48-$1.90Beat
May 1, 2025-$3.62-$3.32Beat

Analyst view

Consensus price target
$686.44 ▲ +56.0%
Range $542.00 – $962.00
Rating: Buy
Buy 88% · Hold 8% · Sell 4%

Get free alerts on MDGL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.